Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipelineDren Bio deep B-cell ...

Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid ...

CERo Therapeutics Holdings, Inc., (NASDAQ: CERO) shares were unchanged. The company, an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that ...

Sanofi to acquire Dren Bio's bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to reset the immune syste ...

Notably, microglia spatially associated with amyloid plaques exhibited increased expression of TREM2 and ApoE compared to ...

Research in the Marine Immunology Program focuses on basic and applied research on the health and immune systems of marine vertebrates, including cartilaginous fishes (sharks, skates, and rays), ...